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A novel Rt-QpCR-based assay 
for the relative quantification 
of residue specific m6A RNA 
methylation
Ainara Castellanos-Rubio1,2,5, Izortze santin3,5, Ane Olazagoitia-Garmendia1, 
Irati Romero-Garmendia1, Amaia Jauregi-Miguel1, Maria Legarda4 & Jose Ramon Bilbao  1,5
N6-methyladenosine (m6A) is the most common and abundant RNA modification. Recent studies have 
shown its importance in the regulation of several biological processes, including the immune response, 
and different approaches have been developed in order to map and quantify m6A marks. However, 
site specific detection of m6A methylation has been technically challenging, and existing protocols 
are long and tedious and often involve next-generation sequencing. Here, we describe a simple RT-
QPCR based approach for the relative quantification of candidate m6A regions that takes advantage 
of the diminished capacity of BstI enzyme to retrotranscribe m6A residues. Using this technique, we 
have been able to confirm the recently described m6A methylation in the 3′UTR of SOCS1 and SOCS3 
transcripts. Moreover, using the method presented here, we have also observed alterations in the 
relative levels of m6A in specific motifs of SOCS genes in celiac disease patients and in pancreatic β-cells 
exposed to inflammatory stimuli.
N6-methyladenosine (m6A) is the most abundant internal modification on mammalian mRNAs and 
long-noncoding RNAs. These modifications are generally dynamic and exhibit changes in distribution or fre-
quency in response to certain stimuli, constituting a new layer of gene regulation termed epitranscriptomics1,2. 
Genetic loss-of-function studies for m6A methyltransferases (m6A writers), m6A-binding proteins (m6A read-
ers), and m6A demethylases (m6A erasers) have highlighted a critical role for m6A modifications in the control 
of gene expression in a range of physiological processes3,4. A recent study analyzing the effects of deleting writer 
Mettl3 in mouse T-cells found that, in the absence of Mettl3, mice develop a chronic inflammation of the intes-
tine and that the mRNAs for STAT signaling inhibitory proteins SOCS1 and SOCS3, that generally present m6A 
methylation marks in their 3′UTR region, exhibited slower decay, resulting in increased mRNA and protein 
levels, and establishing a link between the m6A methylation of those transcripts and T-cell responses5,6. More 
recently, m6A has been shown to affect the LPS-induced inflammatory response in human dental pulp cells7 
opening a new layer of investigation into the molecular mechanisms of inflammatory diseases.
Technological advances in high-throughput sequencing in combination with antibody-enrichment and/
or induced nucleotide-specific chemical modifications have accelerated the mapping of epitranscriptomic 
modifications. However, site-specific detection and quantification of m6A has been technically challeng-
ing8. Methods developed so far involve long and tedious procedures like SCARLET (site-specific cleavage and 
radioactive-labeling followed by ligation-assisted extraction and thin-layer chromatography)9 and miCLIP 
(m6A individual-nucleotide-resolution cross-linking and immunoprecipitation)10 or are based on the dimin-
ished capacity of different nucleic acid polymerases, namely Tth (Thermus thermophiles) and BstI (Bacillus 
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stearothermophilus), to retrotranscribe m6A nucleotides located adjacent to the priming oligo11,12. Flexibility is 
necessary for the processive movement of the enzyme during retrotranscription and the conformational freedom 
between the complex formed by the primer, the template and the enzyme itself is decreased in RNA templates that 
contain m6A residues12,13. Single-nucleotide primer extension with these enzymes followed by polyacrylamide 
gel electrophoresis of the extension products has already been used to quantify the m6A methylation levels of 
specific sites11,12,14. In the present study, we have simplified the protocol while improving accuracy in the relative 
quantification of m6A nucleotides by taking advantage of the inherent reverse transcriptase activity of BstI poly-
merase, hampered in the presence of m6A as previously described by Shi, C et al.15 in combination with relative 
quantification using PCR. We have used this novel m6A-RT-QPCR approach to quantify the m6A levels in spe-
cific residues of human SOCS1 and SOCS3 mRNAs, members of one of the major mechanisms for the regulation 
of cytokine signaling16, in intestinal and β-pancreatic cell lines and in intestinal biopsy samples. Thus, the aim of 
this study was to develop a simple and cost-effective method to relatively quantify the m6A levels of candidate 
transcripts that could contribute to the development of different types of diseases, such as those related to the 
immune system.
Results
m6A-induced reduction in BstI retrotranscription efficiency can be assessed by QPCR. It has 
been previously shown that BstI polymerase has an inherent retrotranscriptase (RT) activity12,15, but we wanted 
to evaluate its capacity to retrotranscribe mRNA using dNTPs instead of a single nucleotide. We designed a 
reverse primer in exon 7 of HPRT gene and performed RT reactions using BstI or M-MuLV RT (MRT) enzymes 
and RNA extracted from HCT15 intestinal cells (Fig. 1A). To verify the ability of BstI for retrotranscription, we 
subsequently amplified the retrotranscription reaction products by PCR using a forward primer in exon 4 and 
a reverse primer in exon 7, which ensures that the product will be derived from mRNA and not from any trace 
of genomic DNA. Both enzymes are able to synthesize cDNA from an mRNA template but, as expected, MRT 
outperforms BstI in retrotranscription efficiency (Fig. 1A).
Having confirmed the retrotranscriptase activity of BstI polymerase in our experimental conditions, we 
wanted to evaluate its ability to reverse transcribe a known m6A residue in the TUG1 lncRNA7. We performed 
Figure 1. (A) Graphical representation of retrotranscription followed by PCR of HPRT (left). Agarose gel 
after PCR of the retrotranscribed samples using BstI and MRT enzymes (right). (B) Graphical representation 
of retrotranscription followed by PCR of TUG1 lncRNA. m6A mark (in green) was described by SCARLET 
method (Liu, N. et al.9) (left). Agarose gel after PCR of the retrotranscribed samples using m6A (+) and (−) 
primers and BstI and MRT enzymes. (C) m6A-RT-QPCR using different time points (5 min, 15 min and 30 min) 
for the retrotranscription of methylated TUG1 and unmethylated HPRT mRNAs. RNA was extracted from three 
different passages of HCT15 intestinal cell line. (D) Relative quantification of m6A levels of TUG1 and HPRT in 
Caco 2 intestinal cells. Data are represented as the mean and standard error of three independent experiments. 
**p-value < 0.01 based on paired Student’s t-test. (E) Comparison of m6A IP data retrieved from the Met-DB 
v2.0 database and relative m6A RT-QPCR results in different genes using the HEK293 cell line. Genes in bold 
showed concordant results using both methods. Grey boxes represent negative (non-methylated) and black 
boxes represent positive (methylated) results. Relative RT-QPCR data correspond to the mean and standard 
error of four independent experiments.
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two RT reactions; one with a primer located adjacent to the test m6A residue, or primer (+), and another one with 
no m6A nearby, or primer (−) (Fig. 1B). After PCR amplification of the RT product, we could detect differences in 
band intensities between the two reactions performed with BstI, suggesting a higher RT efficiency for the reaction 
in which primer (−) was used (Fig. 1B). On the contrary, PCR of the RT products from the MRT reactions sug-
gest that this enzyme is not affected by the proximity of an m6A mark to the primer. In view of these results, we 
hypothesized that those differences in RT efficiency caused by the presence of m6A could be relatively quantified 
by a QPCR step following retrotranscription. In order to test this possibility, HPRT gene was used as a negative 
control for m6A (no methylation marks are described in this transcript), while TUG1 was used as a positive con-
trol. The following formula was stablished for the calculation of the relative m6A levels after QPCR:
= − − − − + − +Relative m6A 2 Ctprimer BstI Ctprimer MRT Ctprimer BstI Ctprimer MRT( ( ) ( ) )/( ( ) ( ) )
Based on these calculations, in the absence of m6A marks, the differences of retrotranscription efficiencies 
between the two enzymes will be similar regardless of the primer used, and the values of the relative m6A quan-
tification will be close to 0.5. In the presence of an m6A residue, due to the decreased retrotranscription ability 
of BstI, the difference in RT efficiencies between enzymes will be more pronounced when using the positive (+) 
primer (adjacent to the m6A residue), resulting in higher values (>0.5) of relative m6A quantification.
In order to determine the best time-point for the quantification of m6A based on the differences in enzyme 
performance, we set up a m6A-RT-QPCR time-course for TUG1 and HPRT genes in RNA samples extracted from 
three different passages of the human HCT15 intestinal cell line. As seen in Fig. 1C, the m6A-positive region in 
TUG1 mRNA showed positive values (above 0.5) in all three time points. However, the m6A-negative region in 
the HPRT gene started to show values above the threshold after 30 minutes of retrotranscription, so all subsequent 
experiments were done after 15 minutes of retrotranscription. Under these conditions, m6A-RT-QPCR analy-
ses confirmed the positive and negative m6A status in TUG1 and HPRT genes, respectively, when using RNA 
extracted from Caco2 intestinal cell line (Fig. 1D), indicating that this method is useful to relatively quantify the 
m6A methylation at a single nucleotide level. To extend the applicability of the method, we quantified relative 
m6A methylation on several additional RNA residues and compared the results with previously published m6A 
immunoprecipitation data of the same regions available at the Met-DB v2.0 database17. For this purpose, we used 
RNA from HEK293 cells as it was the material used in the immunoprecipitation experiments. Eight out of the ten 
gene regions analyzed by relative m6A RT-QPCR method presented concordant results in terms of methylation 
status (methylated/non-methylated) when compared with those available in the database (Fig. 1E) confirming 
the high efficiency of this method.
Fluctuations in m6A levels can be detected using m6A-RT-QPCR. In order to assess the ability of 
this technique to detect fluctuations in m6A levels, the same TUG1 region was in vitro transcribed (IVT) to gener-
ate a single stranded RNA without any methylation. Increasing amounts of non-methylated IVT RNA were mixed 
with RNA extracted from HCT15 cells and the ability to detect m6A marks was quantified. The methylation levels 
of TUG1 residue decreased but remained positive after adding 1500 copies of non-methylated transcript and got 
closer to negative values after adding 150,000 and 1,500,000 copies of the non-methylated RNA (Fig. 2A).
To further confirm the suitability of this method for relative quantification of m6A levels in different RNA 
transcripts in the HCT15 cell line, we used primers adjacent to other described m6A motifs in ACTB mRNA and 
18S RNA9,12. As was the case for TUG1, both transcripts showed methylation in the selected motifs, however, only 
the levels observed in 18S were statistically significant compared to the non-methylated control HPRT (Fig. 2B). 
To determine the ability of this method to quantify m6A fluctuation levels we incubated cells with different con-
centrations of cycloleucine, an inhibitor of m6A methylation18, in order to get RNA with decreased methylation 
percentage. Incubation of cells with 100 mM cycloleucine shows 35% average reduction in the general m6A signal 
detected by RNA Dot-Blot (Fig. 2C) using an anti-m6A antibody. These results were concordant with the relative 
quantification by m6A-RT-QPCR of the TUG1 and 18S regions, which showed a decreased abundance of m6A of 
25% after cycloleucine treatment (Fig. 2D).
Methylation in SOCS1 and SOCS3 3′UTR can be assessed by m6A-RT-QPCR. In order to further 
validate our method for the quantification of m6A levels in additional transcripts, we analyzed the methyla-
tion levels of SOCS1 and SOCS3 mRNAs. The methylation of these two transcripts has been recently associated 
with their stability and subsequently with the ability of T-cells to respond to certain stimuli as the proinflamma-
tory cytokine IL75. As m6A marks in these genes have been described to be located in the 3′UTR, we analyzed 
their sequences in order to find the DRACH m6A consensus motif10. SOCS1 presents a single consensus motif 
(GGACC), m6A-256 (Fig. 3A), while several motifs are found in the SOCS3 gene. For the latter, we selected to 
evaluate one of the two GGACU motifs, m6A-1132, as it has been described to be the most commonly methylated 
sequence (Fig. 3B). We were able to confirm the methylation of the selected regions in both SOCS1 and SOCS3 in 
RNA from intestinal origin using RNA immunoprecipitation with an antibody against m6A followed by QPCR 
(Fig. 3C,D).
We next evaluated the mRNA methylation of SOCS1 and SOCS3 m6A motifs in Caco2 and HCT15 intestinal 
cell lines using our novel m6A-RT-QPCR method. Both intestinal cell lines showed significantly positive levels of 
m6A methylation in the SOCS3 motif (Fig. 3E,F). The methylation levels of SOCS1 reached statistical significance 
only in the HCT15 cells. These results confirm that this method can be used to relatively quantify the m6A meth-
ylation level of a single base in different transcripts.
m6A-RT-QPCR detects inflammation related m6A methylation changes. To assess the ability of 
the m6A-RT-QPCR method to observe methylation changes, we evaluated the alterations in m6A methylation 
of the selected SOCS1 and SOCS3 motifs in different inflammation related scenarios. The mRNA methylation of 
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these genes has been shown to be stimulus-specific in T-cells, where stimulation with IL7 induces m6A methyla-
tion and subsequent degradation of these transcripts5.
Celiac disease (CeD) and type 1 diabetes (T1D) are chronic inflammatory conditions of the small intestine 
and the pancreas, respectively. SOCS genes have been involved in the pathogenesis of these diseases, and it is 
known that celiac and diabetic patients show alterations in these genes at both mRNA and protein levels19,20. We 
used RNA extracted from intestinal biopsy samples of celiac disease patients and non-celiac controls to analyze 
the levels of m6A methylation in the selected motifs of SOCS genes. Similarly to what happened in the intestinal 
cell lines, the SOCS3 motif analyzed presented significantly higher m6A levels compared to HPRT. However, 
SOCS1 levels were only significant in the active disease biopsies (Fig. 4A). The mean methylation of both motifs 
shows a change in the disease status, with a tendency to higher methylation levels for SOCS1 and lower methyla-
tion for SOCS3 motif in the celiac patient group (Fig. 4A). The m6A-RT-QPCR technique was also used to quan-
tify the levels of m6A SOCS gene motifs in in vitro cultured pancreatic β-cells. In this case, cells were stimulated 
with IFNγ and IL1β to simulate the inflammatory environment characteristic of the β-cell destruction that occurs 
in T1D. In contrast to what we had observed in the intestinal biopsies, ß-cells treated with the pro-inflammatory 
cytokines showed no methylation of the SOCS1 motif and a significantly higher methylation of the SOCS3 motif 
(Fig. 4B).
Discussion
N6-Methyladenine (m6A) is the most abundant internal modification on mammalian RNAs constituting a new 
layer of gene regulation that is involved in different biological processes as T-cell response or tumorigenesis5,21. 
Moreover, it has been shown that this modification plays important roles in the development of several disor-
ders, as neuronal disorders, immune-mediated diseases, obesity and cancer2. Although several techniques have 
been developed in order to map and quantify m6A residues9,10,22, available methods are laborious or involve 
next-generation sequencing, so new approaches are needed to measure the m6A levels in selected transcripts that 
could be involved in the development of disease.
In this study we have taken advantage of the previously described diminished capacity of BstI enzyme to 
retrotranscribe m6A nucleotides located adjacent to the priming oligo11,12. Using the method described here we 
have been able to confirm the methylation motifs described by other techniques in TUG1 lncRNA, ACTB mRNA 
and 18S rRNA in intestinal cell lines, in a cost-affordable and time-efficient way. Additionally, when comparing 
the results of specific residues using our method to those of m6A immunoprecipitation experiments, where a 
Figure 2. (A) Relative m6A quantification of TUG1 motif in basal RNA (0) and in RNA mixed with 
increasing amount of copies (1500, 150000 and 1500000) of in vitro transcribed non-methylated RNA.   
*p-value < 0.05 based on paired Student’s t-test. (B) Relative quantification of previously described methylated 
motifs using m6A-RT-QPCR method. **p-value < 0.01 based on paired Student’s t-test. (C) HCT15 cells 
were treated with different concentrations of cycloleucine 3 hours prior to RNA extraction and total RNA was 
evaluated for the quantification of the m6A signal. Representative m6A RNA immuno-dot blot of basal and 
100 mM cycloleucine treatment of 4 independent experiments. Methylene blue staining was used as a loading 
control for RNA amount. (D) Relative quantification of the m6A levels in the selected motifs of TUG1 and 18S 
in RNA extracted from non-treated (−) and 100 mM cycloleucine treated cells. HPRT was used as a negative 
control. Data are represented as the mean and standard error of four independent experiments.
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region is evaluated, we found that the methylation status in concordant in eight out of ten of the RNAs further 
supporting the validity of the method.
This study shows that this method is useful for the relative quantification of a specific residue within a tran-
script. When a non-methylated RNA is added to basal RNA, decreasing the percentage of m6A, or cycloleucine 
is used to reduce the overall RNA methylation levels in the cell, values obtained using m6A-RT-QPCR decreased, 
confirming the validity of the technique to evaluate if a certain residue presents alterations in its methylation rates 
in response to different stimuli or disease status. Although the experiments performed using IVT RNAs suggests 
that m6A percentages as low as 1%, resembling what has been described for SCARLET9, could be detected using 
this technique, the exact percentages are not possible to determine due to the extreme difficulty to artificially 
synthesize a stable RNA with the same characteristics as the regions that are being analyzed (i.e 140 bp).
This technique can be used with limited amounts of RNA extracted from human tissues, that normally are not 
enough to perform  an RNA immunoprecipitation, and the relative amount of m6A marks in candidate regions 
can be easily quantified. We have demonstrated the usefulness of this approach for the quantification of residue 
Figure 3. Location of the m6A motifs in the 3′ sites of the (A) SOCS1 and (B) SOCS3 genes. RNA 
immunoprecipitation of m6A followed by RT-QPCR for the 3′ sites of (C) SOCS1 and (D) SOCS3. Data are 
represented as the mean and standard error of four independent experiments. p-value *p < 0.05. Validation of 
the m6A-RT-QPCR method for the relative quantification of m6A motifs in SOCS1 and SOCS3 genes in RNA 
extracted from (E) HCT15 and (F) Caco2 cells. Data are represented as the mean and standard error of three 
independent experiments. **p-value < 0.01, *p < 0.05; based on paired Student’s t-test.
Figure 4. (A) Relative m6A quantification of selected SOCS1 and SOCS3 motifs in intestinal biopsies of celiac 
patients (n = 8) and controls (n = 6). Data are represented as the mean and standard error of all samples in each 
group. **p-value < 0.01; *<0.05 based on unpaired Student’s t-test. (B) Relative m6A quantification of selected 
SOCS1 and SOCS3 motifs in pancreatic β-cells stimulated with IFNγ and IL1β or without stimulation. Data are 
represented as the mean and standard error of three independent experiments. *p-value < 0.05 based on paired 
Student’s t-test.
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specific methylation in the 3′UTR of SOCS1 and SOCS3 transcripts that were recently described to be regulated 
by m6A modifications in the context of immune response5. Moreover, using this technique, we have shown that 
there are inflammation-related changes in the mRNA methylation of specific motifs of these two genes. It has 
been known for a long time that SOCS proteins play an important part in the fine tuning of the immune response 
and inflammation16 being involved in inflammatory diseases as CeD or T1D, the inflammation-related variability 
of the m6A methylation in these transcripts, and other interesting candidates, could provide progress on the 
understanding on their contribution in disease pathogenesis.
Material and Methods
Biopsies and cell lines. Celiac disease in pediatric patients was diagnosed according to the ESPGHAN 
(European Society of Pediatric Gastroenterology Hematology and Nutrition) criteria in force at the time of 
recruitment, including anti-gliadin (AGA), antiendomysium (EMA) and anti-transglutaminase antibody (TGA) 
determinations as well as a confirmatory small bowel biopsy. The study was approved by the Cruces University 
Hospital Ethics Board and analyses were performed after informed consent was obtained from all subjects or 
their parents. All experiments were performed in accordance with relevant guidelines and regulations. Biopsy 
specimens from the distal duodenum of each patient were obtained during routine diagnosis endoscopy. None 
of the patients suffered from any other concomitant immunological disease. None of the controls showed small 
intestinal inflammation at the time of the biopsy.
Intestinal Caco2 (86010202) and HCT15 (91030712) cell lines were purchased from Sigma Aldrich. HCT15 
cells were incubated with 100 mM cycloleucine (Sigma Aldrich) for 3 hours prior to RNA extraction. The 
EndoC-βH1 human β-cell line (provided by Dr. R. Scharfmann, Centre de Recherche de l’Institut du Cerveau 
et de la Moelle Épinière, Paris, France) was cultured in plates coated with Matrigel-fibronectin (100 mg/ml and 
2 mg/mL, respectively) in low-glucose DMEM as previously described23. Human pancreatic ®-cells were exposed 
to IL-1ß (R&D Systems, Abingdon,U.K.) at 50 units/mL and IFNγ (PeproTech, Rocky Hill, NJ) at 1,000 units/mL 
for 24 h.
RNA, retrotranscription, PCR and QPCR. Total RNA was extracted from cells and biopsies using 
QIAGEN RNA mini kit. All samples were subjected to DNAse I treatment during extraction.
For the m6A-retrotranscription reaction, 75–150 ng of RNA, 100 nM of each primer, 50 ⌠M dNTPs and 
0.1U of BstI (NEB) or 0.8U of MRT (ThermoScientific) were used. The cycling conditions were as follows: 50 °C 
-5/15/30 min, 85 °C-3 min, 4°-∞. For the PCR, 1 ⌠l of the RT reaction was amplified using Dream Taq polymer-
ase (ThermoScientific) and 100 nM of each primer. Cycling conditions were as follows: 95 °C-3min, 40 cycles x 
(95 °C-30sg, 60 °C- 30sg, 72 °C-30sg), 4 °C-∞. For the QCPR, 1.5 ⌠l of the retrotranscription reaction was used 
together with 100 nM of each primer and 2X iTaq SYBR green (BioRad). Reactions were run in an Illumina 
Eco Real Time System and melting curves were analyzed to ensure the amplification of a single product. The 
sequences of all the primers are available upon request.
In vitro transcription (IVT). TUG1 amplicon was reamplified using a forward primer with a T7 sequence. 
After purification, 100 ng of DNA were used for in vitro transcription using T7 polymerase and rNTPs from 
Takara (Clonthech) following manufacturer’s instructions. The IVT product was purified using the Direct-zol 
miniprep kit (Zymo Research).
Dot blot. For cycloleucine experiments 400 ng of RNA were crosslinked into a nitrocellulose membrane using 
UV. Membrane was blocked using 5% milk in 0.1% PBST (0.1% Tween in PBS). Membrane was incubated over-
night with rabbit m6A antibody (1:500) (Abcam, ab151230) at 4 °C followed by an incubation with a secondary 
HRP anti-rabbit antibody. Membrane was developed using SuperSignal West Femto substrate (Thermofisher) in 
a ChemiDoc gel imaging system (Biorad).
m6A RNA immunoprecipitation. 2 μg of RNA per sample were fragmented with RNA fragmentation 
buffer (100 mM Tris, 2 mM MgCl2) for 3 min at 95 °C and placed on ice immediately after heating. 10% of RNA 
was kept as input. 1 µg of m6A antibody (Abcam, ab151230) was coupled to agarose A beads (GE Healthcare) in a 
rotation wheel for 1 h at 4 °C. After incubation, beads were washed twice in reaction buffer (150 mM NaCl, 10 mM 
Tris-HCl, 0.1% NP-40), RNA was added to the antibody coupled beads and incubated for 3 h at 4 °C in a rotating 
wheel. Subsequently, beads were washed 2X in reaction buffer, 2X in low salt buffer (50 mM NaCl, 10 mM TrisHCl 
and 0.1% NP-40) and 2X in high salt buffer (500 mM NaCl, 10 mM TrisHCl and 0.1% NP-40). After the last wash, 
beads were resuspended in Lysis buffer and RNA was extracted using the PureLink RNA extraction kit (Ambion).
Statistical analysis. All experiments were performed in triplicate. The data are represented as the mean 
± standard error of the mean. Comparisons were analyzed by Student’s t test. The significance level was set at 
p < 0.05.
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